eMedicine Specialties > Orthopedic Surgery > Hip

Osteonecrosis, Hip

Author: Michael Levine, MD, Chairman, Department of Orthopedic Surgery, Western Pennsylvania Hospital
Coauthor(s): Amar Rajadhyaksha, MD, Resident, Department of Orthopedic Surgery, New York Medical College; Michael Mont, MD, Associate Professor, Department of Orthopaedic Surgery, Johns Hopkins Medical Institution
Contributor Information and Disclosures

Updated: Mar 26, 2009

Introduction

Osteonecrosis of the femoral head involves the hip joint, with osteocytes of the femoral head dying along with the bone marrow; resorption of the dead tissue by new but weaker osseous tissue can then lead to subchondral fracture and collapse. There are 2 forms of osteonecrosis: traumatic (the most common form) and atraumatic. Other terms to describe this disorder are avascular necrosis and ischemic necrosis to denote vascular etiology. The term aseptic necrosis also has been used to indicate that infection does not play a causative role.

Osteonecrosis, hip. Anteroposterior radiograph sh...

Osteonecrosis, hip. Anteroposterior radiograph showing Ficat stage III disease.

Osteonecrosis, hip. Anteroposterior radiograph sh...

Osteonecrosis, hip. Anteroposterior radiograph showing Ficat stage III disease.


MRI showing osteonecrosis of right hip, normal le...

MRI showing osteonecrosis of right hip, normal left hip.

MRI showing osteonecrosis of right hip, normal le...

MRI showing osteonecrosis of right hip, normal left hip.


Alexander Munro first identified the condition in 1738. In the mid 1800s, Cruveilhier was the first to attribute the disorder to an aberration of circulation in the femoral head. Diagnosis of this disorder has increased because of improved technology and increased awareness.

For excellent patient education resources, visit eMedicine's Breaks, Fractures, and Dislocations Center.

Problem

Osteonecrosis is now a commonly recognized disorder with significant morbidity. The end stage of the process is severe destruction of the femoral head with resultant degeneration of the hip joint. In many patients, even early identification and intervention do not alter the result. Unfortunately, patients who are affected with osteonecrosis are young, usually in the third to sixth decades of life.

Traumatic and atraumatic osteonecrosis are essentially 2 distinct problems. The traumatic form has a definitive causal event and is isolated to the particular injured bone. The atraumatic form has multiple etiologies and can involve multiple bones. The main focus of this article is atraumatic osteonecrosis.

Frequency

Approximately 10,000-20,000 new cases are identified each year in the United States. The traumatic form of hip osteonecrosis occurs in 10% of undisplaced femoral neck fractures, 15-30% of displaced femoral neck fractures, and 10% of hip dislocations.

Corticosteroid use contributes to the atraumatic form of osteonecrosis in 5-25% of patients. The male-to-female ratio is about 4:1. At least 50% of patients with atraumatic hip osteonecrosis are thought to have bilateral involvement. Other bones often are involved in the atraumatic form, including the shoulder, knee, and talus.

Etiology

As the name implies, traumatic osteonecrosis is secondary to direct injury to the femoral head with resultant damage of the blood supply. Fracture of the femoral head or neck and hip dislocation are the primary mechanisms of injury.

Atraumatic osteonecrosis has many risk factors. The 2 most commonly associated problems are corticosteroid use and alcohol abuse. The idiopathic cases make up the third most common category. Other factors include sickle cell anemia, Gaucher disease, systemic lupus erythematosus, coagulopathies, hyperlipidemia, organ transplantation, caisson disease, and thyroid disorders. Genetic factors may also play a role.

Hip osteonecrosis resulting from corticosteroid use or alcohol abuse is associated with the worst prognosis. Frequently, steroid-induced osteonecrosis involves multiple bones and, in the case of the hip, results in nearly 100% bilateral involvement. The exact dose required to induce osteonecrosis remains an enigma, but most studies indicate that higher doses, even over a short duration, present the highest risk. Often, patients on steroids have other associated risk factors.

Osteonecrosis associated with alcohol abuse usually occurs in those who drink more than 400 mL of alcohol per week. It is more common in those with a long-term history of heavy consumption.

Pathophysiology

Traumatic osteonecrosis is a direct result of disruption of the blood supply to the femoral head. Death of bone marrow occurs within 6-12 hours after vascular insult. Death of the bone becomes apparent several days later.

The pathophysiology in atraumatic osteonecrosis remains controversial.1 Fat cell hypertrophy with resultant pressure increase within the femoral head, leading to vascular collapse and then necrosis, has been proposed as a mechanism for steroid-induced osteonecrosis. A fat embolism phenomenon with resultant vascular occlusion is another proposed mechanism. A hyperlipidemic state seems to be related to causation, but the exact mechanism is unknown. Similarly, the lipid hypothesis has also been applied to cases associated with alcohol abuse.

In caisson disease, circulating nitrogen bubbles occlude blood vessels in response to reduction in ambient pressure during decompression. Sickle cell anemia results in bone death secondary to the sickling process and subsequent vascular occlusion.

Increased intraosseous pressure contributes directly to the propagation of necrosis, regardless of etiology. As bone death occurs, a repair process takes place as dead bone is removed and replaced by new bone. During this phase, the bone underlying the joint surface is weakened. In most patients, subchondral fracture alters the articular surface, resulting in abnormal mechanics and arthritic alterations to the joint.

The disease affects both sides of the joint, as confirmed by PET scan imaging showing earlier involvement in the acetabulum than is discernible by other radiographic modalities.

Presentation

Patients with osteonecrosis usually are men in the sixth decade of life who experience pain primarily in the groin but occasionally the buttocks. Pain usually is deep and throbbing and is worse with ambulation, but it also is significant at night. Onset often can be described as acute. Patients frequently describe a catching or popping sensation with motion. A history of trauma, steroid use, alcohol abuse, and other risk factors should be sought.

Physical examination reveals pain with range of motion and ambulation. Limitation of internal rotation in both flexion and extension are prevalent, with passive internal rotation in extension being particularly painful. A Trendelenburg gait often is present.

Plain radiographic findings frequently are normal. Therefore, a high index of suspicion should arise based on the history and physical.

Indications

History and physical examinations are paramount for diagnosis. Treatment is indicated after diagnosis is confirmed with radiographic studies. Most studies indicate that the risk for disease progression is greater with nonsurgical treatment than with surgical intervention.

Relevant Anatomy

Blood is supplied to the femoral head primarily from branches of the medial and lateral circumflex vessels, which arise from the femoral artery. The retinacular branches deep to the posterior capsule are the most important. Blood also is supplied from the obturator artery.

Contraindications

There are few contraindications to surgical treatment of osteonecrosis. Obvious disorders aside (eg, severe systemic disease, systemic sepsis), those afflicted often are young and have few surgical contraindications.

More on Osteonecrosis, Hip

Overview: Osteonecrosis, Hip
Workup: Osteonecrosis, Hip
Treatment: Osteonecrosis, Hip
Follow-up: Osteonecrosis, Hip
Multimedia: Osteonecrosis, Hip
References
Further Reading

References

  1. Aaron RK. Osteonecrosis: etiology, pathophysiology, and diagnosis. In: Callahan JJ, Rosenberg AG, and Rubash HE. The Adult Hip. Philadelphia, Pa:. Lippincott-Raven Publishers;1998:451-66.

  2. Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg [Br]. Jan 1985;67(1):3-9. [Medline].

  3. Steinberg ME, Hayken GD, Steinberg DR. A new method for evaluation and staging of avascular necrosis of the femoral head. In: Arlet J, Ficat,P, Hungerford. Bone Circulation. Baltimore, Md: Williams and Wilkins;1984:398-403.

  4. ARCO Committee on Terminology and Staging. The ARCO perspective for reaching one uniform staging system for osteonecrosis. In: Schoutens pathologic conditions. New York, NY: Plenum Press;1993:375-80.

  5. [Best Evidence] Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. Oct 2005;87(10):2155-9. [Medline].

  6. Wang CJ, Wang FS, Ko JY, Huang HY, Chen CJ, Sun YC, et al. Extracorporeal shockwave therapy shows regeneration in hip necrosis. Rheumatology (Oxford). Apr 2008;47(4):542-6. [Medline].

  7. Stiehl JB, Ulrich SD, Seyler TM, Bonutti PM, Marker DR, Mont MA. Bone morphogenetic proteins in total hip arthroplasty, osteonecrosis and trauma surgery. Expert Rev Med Devices. Mar 2008;5(2):231-8. [Medline].

  8. Jones KB, Seshadri T, Krantz R, Keating A, Ferguson PC. Cell-based therapies for osteonecrosis of the femoral head. Biol Blood Marrow Transplant. Oct 2008;14(10):1081-7. [Medline].

  9. Nadeau M, Séguin C, Theodoropoulos JS, Harvey EJ. Short term clinical outcome of a porous tantalum implant for the treatment of advanced osteonecrosis of the femoral head. Mcgill J Med. Jan 2007;10(1):4-10. [Medline].

  10. Stulberg BN, Davis AW, Bauer TW. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clin Orthop. Jul 1991;(268):140-51. [Medline].

  11. Tanzer M, Bobyn JD, Krygier JJ, Karabasz D. Histopathologic retrieval analysis of clinically failed porous tantalum osteonecrosis implants. J Bone Joint Surg Am. Jun 2008;90(6):1282-9. [Medline].

  12. Mont MA, Einhorn TA, Sponseller PD. The trapdoor procedure using autogenous cortical and cancellous bone grafts for osteonecrosis of the femoral head. J Bone Joint Surg Br. Jan 1998;80(1):56-62. [Medline].

  13. Beaty JH. Osteonecrosis. In: Orthopedic Knowledge. Update 6. Rosemont, Ill:. American Academy of Orthopedic Surgery;1999:460-5.

  14. Bradway JK, Morrey BF. The natural history of the silent hip in bilateral atraumatic osteonecrosis. J Arthroplasty. Aug 1993;8(4):383-7. [Medline].

  15. Kerboul M, Thomine J, Postel M. The conservative surgical treatment of idiopathic aseptic necrosis of the femoral head. J Bone and Joint Surg. 1974;56-B(2):291-96. [Medline].

  16. Lavernia CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. J Am Acad Orthop Surg. Jul-Aug 1999;7(4):250-61. [Medline].

  17. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am. Mar 1995;77(3):459-74. [Medline].

  18. Petty W. Osteonecrosis: Strategies for treatment. In: Callahan, Rosenberg AG, and Rubashed HE. The Adult Hip. Philadelphia, Pa:. Lippincott-Raven Publishers;1998:467-84.

  19. Steinberg ME, Corces A, Fallon M. Acetabular involvement in osteonecrosis of the femoral head. J Bone Joint Surg Am. Jan 1999;81(1):60-5. [Medline].

  20. Stulberg BN, Bauer TW, Belhobek GH. A diagnostic algorithm for osteonecrosis of the femoral head. Clin Orthop. Dec 1989;(249):176-82. [Medline].

  21. Urbaniak JR, Harvey EJ. Revascularization of the femoral head in osteonecrosis. J Am Acad Orthop Surg. Jan-Feb 1998;6(1):44-54. [Medline].

Keywords

hip osteonecrosis, aseptic necrosis, avascular necrosis, osteonecrosis of the femoral head, ischemic necrosis, protein C deficiency, protein S deficiency, sickle cell anemia

Contributor Information and Disclosures

Author

Michael Levine, MD, Chairman, Department of Orthopedic Surgery, Western Pennsylvania Hospital
Michael Levine, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Association of Hip and Knee Surgeons, American Medical Association, Orthopaedic Research Society, Pennsylvania Medical Society, Pennsylvania Orthopaedic Society, and Phi Beta Kappa
Disclosure: encore medical Consulting fee Consulting; glaxo smith kline Honoraria Speaking and teaching

Coauthor(s)

Amar Rajadhyaksha, MD, Resident, Department of Orthopedic Surgery, New York Medical College
Disclosure: Nothing to disclose.

Michael Mont, MD, Associate Professor, Department of Orthopaedic Surgery, Johns Hopkins Medical Institution
Michael Mont, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons
Disclosure: Stryker Orthopaedics Consulting fee Consulting; Wright Medical Technology, Inc. Consulting fee Consulting

Medical Editor

B Sonny Bal, MD, Associate Professor, Department of Orthopedic Surgery, University of Missouri School of Medicine
B Sonny Bal, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

James J McCarthy, MD, FAAOS, FAAP, Associate Professor, Consulting Orthopedic Surgeon, Department of Orthopedics and Rehabilitation, University of Wisconsin School of Medicine and Public Health;
James J McCarthy, MD, FAAOS, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Orthopaedic Surgeons, American Academy of Pediatrics, American Orthopaedic Association, Limb Lengthening and Reconstruction Society ASAMI-North America, Orthopaedics Overseas, Pediatric Orthopaedic Society of North America, Pennsylvania Medical Society, Pennsylvania Orthopaedic Society, and Philadelphia County Medical Society
Disclosure: Nothing to disclose.

CME Editor

Dinesh Patel, MD, FACS, Associate Clinical Professor of Orthopedic Surgery, Harvard Medical School; Chief of Arthroscopic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital
Dinesh Patel, MD, FACS is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Association of Physicians of Indian Origin, American College of International Physicians, and American College of Surgeons
Disclosure: Nothing to disclose.

Chief Editor

Carlos J Lavernia, MD, FAAOS, Adjunct Clinical Professor, Department of Orthopedic Surgery, University of Miami School of Medicine; Medical Director, Orthopedic Institute at Mercy Hospital
Carlos J Lavernia, MD, FAAOS is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Association of Hip and Knee Surgeons, Arthritis Foundation, Biomedical Engineering Society, Florida Orthopaedic Society, and Orthopaedic Research Society
Disclosure: Zimmer Stock Implant Designer

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.